← Search & browse all drugs

papillomavirus (human types 6, 11, 16, 18)

J07BM01

Forms & Strengths

Suspension for injection: 0.5ml single-dose vials, and prefilled syringes
Each 0.5ml dose contains: 20mcg HPV 6, 40mcg HPV 11, 40mcg HPV 16, and 20mcg HPV 18

Adult Dosing

0.5ml dose IM at 0, 2, and 6 months for males and females 9-26 years
For individuals with weakened immune systems, a 3-dose series may be given
Catch-up vaccination recommended through age 26 for those not vaccinated when younger

Pediatric Dosing

First dose at age 11-12 years, though can start as young as 9 years
Typical series of 2 doses at 0 and 6-12 months for immunocompetent children
For immunocompromised children, the series may be 3 doses at 0, 2, and 6 months

Indications

Prevention of anal, cervical, vulvar, and vaginal cancers and their precursors
Prevention of genital warts (condyloma acuminata) caused by HPV types 6 and 11
Prevention of oropharyngeal and other head and neck cancers

Mechanism of Action

Stimulates the body to produce antibodies that help protect against HPV
Induces neutralizing antibodies against the L1 capsid protein of HPV types 6, 11, 16, and 18
Does not provide therapeutic effect against established infection or disease

Contraindications

Severe allergic reaction to any component of the vaccine or after a previous dose
Moderate or severe acute illness, though mild acute illness is not a contraindication

Adverse Reactions

Pain, redness, or swelling at the injection site
Fatigue, headache, or muscle or joint pain
Fever, nausea, dizziness, or fainting

Drug Interactions

No known interactions with other vaccines
May be administered concomitantly with other vaccines or medications
No interaction with hormonal contraceptives

Curated Content: Needs Vetting Before Put to Clinical Use